drugset / Trial / NCT00983541

Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma

NCT00983541 ↗

Phase 2 Terminated 1 enrolled University of Utah
NaSingle-groupOpen-labelTreatment

Summary

OBJECTIVES: This study proposes to evaluate the feasibility of delivery of this treatment in terms of toxicity. If toxicity is not acceptable, the treatment is not feasible. Primary Objectives * To establish a preliminary assessment whether toxicity rates are acceptable in patients with locally advanced intra or extrahepatic cholangiocarcinoma when treated with a regimen of gemcitabine every two weeks and continuous fluorouracil (5-FU) given concurrently with external beam radiation therapy to a total dose of 45 gray(Gy), followed by a brachytherapy or Stereotactic Body Radiation Therapy(SBRT) boost. Secondary Objectives * To evaluate the overall survival rate, progression free survival rate, tumor response rate, local control rate and the rate of distant metastases following gemcitabine and continuous 5-FU concurrent with radiation therapy in patients with locally advanced intra or extrahepatic cholangiocarcinoma. * To evaluate the rate at which patients with unresectable extrahepatic cholangiocarcinoma become resectable following gemcitabine and radiation therapy.

Timeline

Start
2009-09
Primary completion
2012-03
Completion
2012-03

Outcome

Outcome not reported

Stopped (Enrollment): “Low enrollment”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule — —
Subject fluorouracil Small molecule 350 mg/m2 —

Indications